Community hub
Broxaterol
View on Wikipedia | |
| Names | |
|---|---|
| IUPAC name
1-(3-Bromo-5-isoxazolyl)-2-(tert-butylamino)ethanol
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.071.338 |
| MeSH | Broxaterol |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C9H15BrN2O2 | |
| Molar mass | 263.135 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Broxaterol is a β2 adrenoreceptor agonist.[1] It is part of a class of drugs that affect the smooth muscle receptors in the body, often in use cases for respiratory disease that respond to this type of treatment.
Synthesis
[edit]
The 1,3-dipolar cycloaddition between bromonitrile oxide, produced in situ from dibromoformaldoxime, and 3-butyn-2-one gives a mixture of isoxazoles, mainly the isomer shown required for broxaterol. Selective α-bromination of the acetyl group with pyridinium tribromide gives a bromoketone whose carbonyl group is reduced with sodium borohydride to produce a bromoethanol derivative. Treatment of this with tert-butylamine yields broxaterol.[2][3][4][5]
References
[edit]- ^ Nava S, Crotti P, Gurrieri G, Fracchia C, Rampulla C (January 1992). "Effect of a beta 2-agonist (broxaterol) on respiratory muscle strength and endurance in patients with COPD with irreversible airway obstruction". Chest. 101 (1): 133–40. doi:10.1378/chest.101.1.133. PMID 1345900.
{{cite journal}}: CS1 maint: deprecated archival service (link) - ^ US patent 4276299, Davide Della Bella and Dario Chiarino, "1-(3-Bromo-isoxazol-5-yl)-2-tert.butylaminoethanol", issued 1981-06-30, assigned to Zambon SpA
- ^ De Amici, Marco; De Micheli, Carlo; Carrea, Giacomo; Spezia, Sandro (1989). "Chemoenzymatic synthesis of chiral isoxazole derivatives". The Journal of Organic Chemistry. 54 (11): 2646–2650. doi:10.1021/jo00272a037.
- ^ Rohloff, John C.; Robinson, James; Gardner, John O. (1992). "Bromonitrile oxide [3+2] cycloadditions in water". Tetrahedron Letters. 33 (22): 3113–3116. doi:10.1016/S0040-4039(00)79827-3.
- ^ Battilocchio, Claudio; Bosica, Francesco; Rowe, Sam M.; et al. (2017). "Continuous Preparation and Use of Dibromoformaldoxime as a Reactive Intermediate for the Synthesis of 3-Bromoisoxazolines". Organic Process Research & Development. 21 (10): 1588–1594. doi:10.1021/acs.oprd.7b00229.
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by adding missing information. |